Ginkgo Bioworks announced that its Datapoints offering is launching ADME-One^™, a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio. ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management. The launch builds on the three companies' strategic partnership, announced in August 2025, to deploy AI-driven, lab-in-the-loop workflows across the biopharma industry. 

ADME-One is designed to break a cycle that has constrained small molecule drug discovery for decades: Due to the economic limitations of traditional data generation methods, comprehensive ADME profiling is typically reserved for lead optimization after teams have determined their lead series. When liabilities surface at this later stage, the cost of fixing them is highest. ADME-One changes that calculus, allowing discovery teams to characterize entire series with integrated, data-driven decisions in stages as early as hit identification. The result is fewer surprises, fewer wasted synthesis cycles, and a better ability to identify and test the compounds most likely to succeed in humans.

A Single, Integrated Workflow Across Three Category Leaders

ADME-One unites three best-in-class capabilities in one packaged service:

• Ginkgo Datapoints: Data Generation. All five Tier 1 assays (microsomal stability, cell permeability, kinetic solubility, CYP inhibition, and plasma protein binding) are executed end-to-end in Ginkgo's automated laboratory in Boston. Validated, standardized workflows produce AI-ready data without the variability of manual handling.
• Inductive Bio: AI-Driven Contextualization. Inductive Bio's Compass platform turns the experimental panel into actionable human PK projections, integrating disparate individual ADME datapoints into a single multiparameter optimization endpoint that guides compound prioritization. The company's ADMET models are independently validated as best-in-class, having recently won both the 2025 ASAP and 2026 ExpansionRx OpenADMET blind prediction challenges, two of the most rigorous public benchmarks in the field.
• Tangible Scientific: Compound Management. Customers submit compounds and receive results. Tangible handles compound intake, plating, real-time tracking, and management for every ADME-One order, eliminating the logistics overhead that typically accompanies outsourced ADME work.

Impact on Drug Discovery

"With ADME-One, we're both lowering the price of an ADME panel and transforming when and to what extent this data is effectively used in the drug discovery process," said John Androsavich, General Manager at Ginkgo Datapoints. "For the first time, chemists can efficiently characterize the entire series in hit identification. That fundamentally changes the quality of decisions teams make at the earliest stages of a program, where derisking is most needed. By combining automation, AI, and integrated logistics in a single domestic workflow, Ginkgo and our partners are demonstrating and making available the workflows that the Bio × AI era of drug discovery demands."

"We are at a moment in the application of AI to medicine where discovery teams can generate and prioritize drug candidates faster than their physical operations can validate them. Manifests get reconciled by hand, orders move through email threads, and senior scientists spend hours per week chasing shipments and tracking inventory across vendors. Tangible's role in ADME-One is to make the handoffs between design and data disappear, so discovery teams can validate candidates at the speed their AI investments promised," said Adham Chebbani, Co-founder of Tangible Scientific.

"The question every drug program is really trying to answer is which compound is most likely to achieve a safe and efficacious human dose," said Josh Haimson, CEO at Inductive Bio. "The Inductive platform lets drug hunters rank millions of compounds by predicted human dose, using state-of-the-art AI models that placed first in both OpenADMET competitions. With ADME-One, we move those compounds from the virtual lab to the wet lab in a tight feedback loop, surfacing the most promising ideas from day one. This is what AI-driven discovery looks like in practice: better decisions earlier, fewer dead ends later, and higher-quality medicines reaching patients sooner."

Together, the three partners deliver unified, contextualized ADME data in a streamlined workstream with rapid turnaround, all at a price point several times lower than the industry standard. Against the backdrop of U.S. and European drug developers reshoring preclinical efforts in response to the BIOSECURE Act and growing demand for data sovereignty, ADME-One delivers a fully U.S.-based workflow at pricing that beats offshore alternatives. Automated workflows return results in days rather than weeks, and because every run is standardized, each screening campaign contributes to better future predictions, delivering the volume, consistency, and metadata richness that AI-driven discovery depends on.

To drive ADME-One's product strategy, Ginkgo Datapoints has added Jonathan Grob to its leadership team as Vice President of Small Molecules. Grob brings deep expertise in medicinal chemistry, automation, and technology development from prior roles at Novartis and Valo Health. His hire reflects Ginkgo's continued investment in building the strongest next-generation, AI-enabled small molecule drug discovery team in the industry, complementing the platform's automation and data generation capabilities with seasoned scientific leadership.